Takeda Buys Global Rights to Soticlestat for Rare Epileptic Disorders

Takeda Buys Global Rights to Soticlestat for Rare Epileptic Disorders

291213

Takeda Buys Global Rights to Soticlestat for Rare Epileptic Disorders

Takeda Pharmaceuticals has acquired the global rights to develop and market the investigational oral therapy soticlestat (OV935/TAK-935) for developmental and epileptic encephalopathies, including Dravet syndrome, the company has announced. Soticlestat was originally developed by Takeda and Ovid Therapeutics, after the companies entered into a collaboration in 2017. Under the new agreement, Takeda is solely responsible for the worldwide development and commercialization of soticlestat, with Ovid having no financial obligations to Takeda under the original agreement. Takeda now…

You must be logged in to read/download the full post.